TY  - JOUR
AU  - Alba, Emilio
AU  - Lluch, Ana
AU  - Ribelles, Nuria
AU  - Anton-Torres, Antonio
AU  - Sanchez-Rovira, Pedro
AU  - Albanell, Joan
AU  - Calvo, Lourdes
AU  - García-Asenjo, Jose Antonio Lopez
AU  - Palacios, Jose
AU  - Chacon, Jose Ignacio
AU  - Ruiz, Amparo
AU  - De la Haba-Rodriguez, Juan
AU  - Segui-Palmer, Miguel A
AU  - Cirauqui, Beatriz
AU  - Margeli, Mireia
AU  - Plazaola, Arrate
AU  - Barnadas, Agusti
AU  - Casas, Maribel
AU  - Caballero, Rosalia
AU  - Carrasco, Eva
AU  - Rojo, Federico
PY  - 2016
DO  - 10.1634/theoncologist.2015-0312
UR  - http://hdl.handle.net/10668/9746
T2  - The oncologist
AB  - In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary endocrine treatment efficacy, but its value as a predictor of response to chemotherapy is still controversial. We analyzed 262 patients with centralized...
LA  - en
KW  - Breast cancer
KW  - Chemosensitivity
KW  - Ki67
KW  - Neoadjuvant chemotherapy
KW  - Predictive factor
KW  - Adult
KW  - Aged
KW  - Breast Neoplasms
KW  - Clinical Trials as Topic
KW  - Disease-Free Survival
KW  - Estrogen Receptor alpha
KW  - Female
KW  - Humans
KW  - Ki-67 Antigen
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Predictive Value of Tests
KW  - Prognosis
KW  - Receptor, ErbB-2
TI  - High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
TY  - research article
VL  - 21
ER  -